AbbVie sees a megablockbuster in Vraylar. Could a new depression indication push peak sales past $4B?

Nicole DeFeudis

Editor

Despite a bumpy takeoff, AbbVie has some big plans for Vraylar, the blockbuster schizophrenia and bipolar drug it snapped up from Allergan a couple of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie sees a megablockbuster in Vraylar. Could a new depression indication push peak sales past $4B?

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Ab­b­Vie sees a megablock­buster in Vray­lar. Could a new de­pres­sion in­di­ca­tion push peak sales past $4B?

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

AbbVie sees a megablockbuster in Vraylar. Could a new depression indication push peak sales past $4B?